TY - JOUR
T1 - The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21
T2 - Findings from clinical practice
AU - Salar, Antonio
AU - Haioun, Corinne
AU - Rossi, Francesca G.
AU - Duehrsen, Ulrich
AU - Pettengell, Ruth
AU - Johnsen, Hans E.
AU - Jaeger, Ulrich
AU - Verhoef, Gregor
AU - Schwenkglenks, Matthias
AU - Bacon, Pamela
AU - Bendall, Kate
AU - Lugtenburg, Pieternella J.
PY - 2012/5
Y1 - 2012/5
N2 - Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated with substantial myelotoxicity in both high- and low-risk groups. In a multivariate analysis, older age, poor performance status, lower baseline hemoglobin, and lack of G-CSF prophylaxis were significantly associated with occurrence of FN in any cycle. Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery.
AB - Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated with substantial myelotoxicity in both high- and low-risk groups. In a multivariate analysis, older age, poor performance status, lower baseline hemoglobin, and lack of G-CSF prophylaxis were significantly associated with occurrence of FN in any cycle. Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery.
KW - Diffuse large B-cell lymphoma
KW - Febrile neutropenia
KW - Granulocyte colony stimulating factor
KW - R-CHOP-21
KW - Relative dose intensity
KW - Risk assessment
UR - http://www.scopus.com/inward/record.url?scp=84858748086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84858748086&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2012.02.002
DO - 10.1016/j.leukres.2012.02.002
M3 - Article
C2 - 22385870
AN - SCOPUS:84858748086
VL - 36
SP - 548
EP - 553
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 5
ER -